152 related articles for article (PubMed ID: 36198279)
1. Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging: Diagnostic Pathways and Metabolites for Renal Tumor Entities.
Erlmeier F; Sun N; Shen J; Feuchtinger A; Buck A; Prade VM; Kunzke T; Schraml P; Moch H; Autenrieth M; Weichert W; Hartmann A; Walch A
Oncology; 2023; 101(2):126-133. PubMed ID: 36198279
[TBL] [Abstract][Full Text] [Related]
2. MALDI Mass Spectrometry Imaging-Prognostic Pathways and Metabolites for Renal Cell Carcinomas.
Erlmeier F; Sun N; Shen J; Feuchtinger A; Buck A; Prade VM; Kunzke T; Schraml P; Moch H; Autenrieth M; Weichert W; Hartmann A; Walch A
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406537
[TBL] [Abstract][Full Text] [Related]
3. How Suitable is Matrix-Assisted Laser Desorption/Ionization-Time-of-Flight for Metabolite Imaging from Clinical Formalin-Fixed and Paraffin-Embedded Tissue Samples in Comparison to Matrix-Assisted Laser Desorption/Ionization-Fourier Transform Ion Cyclotron Resonance Mass Spectrometry?
Buck A; Balluff B; Voss A; Langer R; Zitzelsberger H; Aichler M; Walch A
Anal Chem; 2016 May; 88(10):5281-9. PubMed ID: 27065343
[TBL] [Abstract][Full Text] [Related]
4. Imaging Mass Spectrometry Is an Accurate Tool in Differentiating Clear Cell Renal Cell Carcinoma and Chromophobe Renal Cell Carcinoma: A Proof-of-concept Study.
Lu HC; Patterson NH; Judd AM; Reyzer ML; Sehn JK
J Histochem Cytochem; 2020 Jun; 68(6):403-411. PubMed ID: 32466698
[TBL] [Abstract][Full Text] [Related]
5. Leptin and its receptor: can they help to differentiate chromophobe renal cell carcinoma from renal oncocytoma?
Ng KL; Del Vecchio SJ; Samaratunga H; Morais C; Rajandram R; Vesey DA; Wood ST; Gobe GC
Pathology; 2018 Aug; 50(5):504-510. PubMed ID: 29970253
[TBL] [Abstract][Full Text] [Related]
6. [Expression of GPNMB in renal eosinophilic tumors and its value in differential diagnosis].
Wang Y; Hou MY; Fu Y; Meng K; Wu HY; Chen J; Xu YM; Shi J; Fan XS
Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):358-363. PubMed ID: 36973196
[No Abstract] [Full Text] [Related]
7. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
8. Sporadic oncocytic tumors with features intermediate between oncocytoma and chromophobe renal cell carcinoma: comprehensive clinicopathological and genomic profiling.
Liu YJ; Ussakli C; Antic T; Liu Y; Wu Y; True L; Tretiakova MS
Hum Pathol; 2020 Oct; 104():18-29. PubMed ID: 32673684
[TBL] [Abstract][Full Text] [Related]
9. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
[TBL] [Abstract][Full Text] [Related]
11. Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy.
Kriegsmann M; Casadonte R; Maurer N; Stoehr C; Erlmeier F; Moch H; Junker K; Zgorzelski C; Weichert W; Schwamborn K; Deininger SO; Gaida M; Mechtersheimer G; Stenzinger A; Schirmacher P; Hartmann A; Kriegsmann J; Kriegsmann K
J Cancer; 2020; 11(20):6081-6089. PubMed ID: 32922548
[No Abstract] [Full Text] [Related]
12. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
[TBL] [Abstract][Full Text] [Related]
13. Distinguishing Renal Cell Carcinoma From Normal Kidney Tissue Using Mass Spectrometry Imaging Combined With Machine Learning.
Shankar V; Vijayalakshmi K; Nolley R; Sonn GA; Kao CS; Zhao H; Wen R; Eberlin LS; Tibshirani R; Zare RN; Brooks JD
JCO Precis Oncol; 2023 Jun; 7():e2200668. PubMed ID: 37285559
[TBL] [Abstract][Full Text] [Related]
14. Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens.
Kriegsmann M; Casadonte R; Kriegsmann J; Dienemann H; Schirmacher P; Hendrik Kobarg J; Schwamborn K; Stenzinger A; Warth A; Weichert W
Mol Cell Proteomics; 2016 Oct; 15(10):3081-3089. PubMed ID: 27473201
[TBL] [Abstract][Full Text] [Related]
15. Identification of diagnostic metabolic signatures in clear cell renal cell carcinoma using mass spectrometry imaging.
Vijayalakshmi K; Shankar V; Bain RM; Nolley R; Sonn GA; Kao CS; Zhao H; Tibshirani R; Zare RN; Brooks JD
Int J Cancer; 2020 Jul; 147(1):256-265. PubMed ID: 31863456
[TBL] [Abstract][Full Text] [Related]
16. Histo-molecular differentiation of renal cancer subtypes by mass spectrometry imaging and rapid proteome profiling of formalin-fixed paraffin-embedded tumor tissue sections.
Möginger U; Marcussen N; Jensen ON
Oncotarget; 2020 Nov; 11(44):3998-4015. PubMed ID: 33216824
[TBL] [Abstract][Full Text] [Related]
17. Combined Immunohistochemistry for the "Three 7" Markers (CK7, CD117, and Claudin-7) Is Useful in the Diagnosis of Chromophobe Renal Cell Carcinoma and for the Exclusion of Mimics: Diagnostic Experience from a Single Institution.
Zhou J; Yang X; Zhou L; Zhang P; Wang C
Dis Markers; 2019; 2019():4708154. PubMed ID: 31737127
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
19. Defining the human kidney N-glycome in normal and cancer tissues using MALDI imaging mass spectrometry.
Drake RR; McDowell C; West C; David F; Powers TW; Nowling T; Bruner E; Mehta AS; Angel PM; Marlow LA; Tun HW; Copland JA
J Mass Spectrom; 2020 Apr; 55(4):e4490. PubMed ID: 31860772
[TBL] [Abstract][Full Text] [Related]
20. Quantitative computer-aided diagnostic algorithm for automated detection of peak lesion attenuation in differentiating clear cell from papillary and chromophobe renal cell carcinoma, oncocytoma, and fat-poor angiomyolipoma on multiphasic multidetector computed tomography.
Coy H; Young JR; Douek ML; Brown MS; Sayre J; Raman SS
Abdom Radiol (NY); 2017 Jul; 42(7):1919-1928. PubMed ID: 28280876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
